Interim results from the GOZILA study in patients with metastatic colorectal cancers (CRC), further showed that ctDNA analysis can be equally as informative as tumour tissues, for the identification of patients with HERC2-amplified metastatic CRC, who can benefit from dual HERC2-targeted therapy (trastuzumab and pertuzumab combination) [98]. Here, HERC2 is linked to neoplasm.